Brolucizumab in the management of Diabetic Macular Edema (DME) and Age-Related Macular Degeneration (AMD): An In-depth evaluation through a Case Series.

Author: Moniruzzaman et al. Summary: Anti-VEGF therapies have emerged as the standard treatment for age-related macular degeneration (AMD) and diabetic macular edema (DME), leading to a significant reduction in vision loss. However, the frequent injections required for these therapies impose a burden on patients, caregivers, and the healthcare system. Additionally, maintaining long-term visual improvement can be challenging. To address these issues, Brolucizumab, an intravitreal anti-VEGF therapy, has been approved for the treatment of AMD and DME. It offers a longer duration of action and a drying effect, potentially reducing the need for frequent injections and providing an effective treatment option.

By |December 22nd, 2023|Categories: |Tags: |0 Comments
Go to Top